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Conclusions: In conclusion, synchrotron based FTIR spectroscopy 
could become a tool to assess tumour cell sensitivity to chemotherapy 
agents, and to help pathologists in the diagnosis of cancer. We’ll dis-
cuss here its use as a screening tool to assess the effects of new drugs 
on cancer cells, and to characterise biomarkers of sensitivity of cancer 
cells to drugs. Also, we’ll discuss here its potential as a screening tool 
to assess the absence or presence of tumour cells in tissue samples 
based on spectral biomarkers.
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Introduction: Non-small cell lung cancer (NSCLC) is the most fre-
quent malignant disease of the respiratory system. Due to an insidious 
onset and early distant dissemination of NSCLC, results of treatment of 
even locally non-advanced stages of the disease are highly unsatisfac-
tory. Telomerase activity could be one of prognostic factors, not related 
to the clinical advancement of cancer. 
The Aim of the Study: Evaluation of the relationship between telom-
erase activity in transthoracic ﬁne-needle biopsy (TFNB) aspirates 
taken from peripheral NSCLC, cancer advancement, risk of death and 
survival free of cancer recurrence. 
Material and Methods: The study group consisted of 88 patients 
with peripheral inﬁltration of the lung. All of them had TFNB of the 
focal lesion performed. Aspirates were subjected to standard cytologi-
cal evaluation. Additionally, telomerase activity in the specimens was 
determined with the PCR-ELISAPLUS method. NSCLC advancement 
was assessed according to the WHO criteria. The manner of cancer 
treatment and patient survival were assessed. 
Results: NSCLC was newly diagnosed in 79 subjects: 20 patients 
(25.3%) with stage I, 15 (19.0%) with stage II, 22 (27.85%) with stage 
III, and 22 (27.85%) with stage IV. In 9 cases, a benign lesion of the 
lung parenchyma was recognized. An increased telomerase activity was 
observed in 10 (50%) patients with stage I, in 8 (53%) patients with 
stage II, in 16 (73%) patients with stage III and 22 (100%) patients 
with stage IV. Nobody with benign inﬁltration had a detectable level 
of telomerase. It was revealed (log-linear analysis) that the higher 
telomerase activity in primary tumor, the more probable non-operable 
NSCLC and cancer metastases to distant organs. An increased telom-
erase activity in TFNB aspirates was related to 7 times higher relative 
risk of death during the study [RR = 6.9 (CI: 1.8-26.8); p < 0.05]. 
NSCLC recurrence after radical treatment appeared only in 1 (6.2%) 
case without an increased telomerase activity in comparison to 6 (20%) 
cases with a detectable telomerase level [RR = 2.5 (CI: 0.3-19.3); p < 
0.05]. Telomerase activity in aspirates derived from TFNB of peripher-
al NSCLC could be a helpful independent signiﬁcant prognostic factor 
of lung cancer advancement and risk of death or cancer recurrence.
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Background: TARSH (Target of NESH-SH3) is a presumptive signal 
transduction molecule interacting with NESH which is implicated to 
have some roles in lung cancer metastasis. We have previously found 
evidence for TARSH being predominantly expressed in the mouse lung 
and being induced during cellular senescence of mouse embryonic 
ﬁbroblasts. On the basis of relationship between cellular senescence 
and carcinogenesis, we analyzed TARSH mRNA expression in human 
primary lung cancer.
Methods: Fifteen human lung cancer cell lines and 80 clinical cancer 
specimens were analyzed in this study. Both neoplastic and non-neo-
plastic tissue samples were obtained from patients who underwent sur-
gery for primary lung cancer: 58 for adenocarcinoma including 10 of 
bronchioloalveolar carcinoma (BAC), 17 for squamous cell carcinoma, 
and 5 for the others (including 3 of large cell carcinoma and 2 of small 
cell carcinoma). Total RNA was extracted from each sample, followed 
by quantitative real-time reverse transcription PCR with SYBR Green. 
The expression level of TARSH in each sample was normalized with 
respect to that of GAPDH. We then deﬁned T/N ratio as the ratio of the 
average mRNA expression levels for each clinical cancer specimen to 
that of corresponding non-neoplastic lung tissue.
Results: On the Northern hybridization analysis, TARSH was strongly 
expressed in the human normal lung. In 15 human lung cancer cell lines 
tested, TARSH expression was completely lost or remarkably down-
regulated as demonstrated by quantitative real-time RT-PCR. We found 
that TARSH expression level was reduced in all cancer specimens 
when compared with the non-neoplastic lung tissue obtained from the 
same patient. The T/N ratio in adenocarcinoma, squamous cell carci-
noma and the others was 0.126 (in a range from 0.003 to 0.832), 0.011 
(from 0.001 to 0.035) and 0.072 (from 0.001 to 0.231) respectively. In 
particular, BAC showed relatively higher T/N ratio than others. There 
was some correlation between TARSH expression and clinicopatho-
logical characteristics when applied multi-parametric analysis.
Conclusions: The expression of TARSH mRNA was remarkably 
downregulated in all lung cancer cell lines examined, and signiﬁcantly 
low in all (80 cases) of the lung cancer specimens when compared to 
the expression in corresponding non-neoplastic lung tissue specimens. 
The cancer-associated transcriptional inactivation of TARSH suggests 
that TARSH could be used as a biomarker for lung cancer development.
